Outcomes of digoxin vs. beta-blocker in AF: report from ESC-EHRA EORP-AF Long-Term General Registry.

Ding W. Y., Boriani G., Marin F., Blomström-Lundqvist C., Potpara T. S., Fauchier L., ...Daha Fazla

European heart journal. Cardiovascular pharmacotherapy, cilt.8, ss.372-382, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1093/ehjcvp/pvab076
  • Dergi Adı: European heart journal. Cardiovascular pharmacotherapy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.372-382
  • Anahtar Kelimeler: Atrial fibrillation, Digoxin, Beta blocker, Rate control, Mortality, Hospitalizations, Quality of life, Permanent AF, Heart failure, CKD, EORP-AF, Registry, HEART-FAILURE, INCREASED MORTALITY, RISK, METAANALYSIS, GUIDELINES, MANAGEMENT, EFFICACY, STROKE
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Aims The safety of digoxin therapy in atrial fibrillation (AF) remains ill-defined. We aimed to evaluate the effects of digoxin over beta-blocker therapy in AF.